Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 9/20 | 0.36 |
| ▸ | PDE1A | P54750 | 5/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE8B | O95263 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.31 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12775446 | 0.84 | PDE1B (0.51) | PDE5APDE1BPDE1APDE1CPDE2A | |
| SCHEMBL12775449 | 0.74 | PDE5A (0.62) | PDE5APDE1BPDE1APDE1CPDE2A | |
| SCHEMBL24067423 | 0.73 | KDM4E (0.40) | PDE5APDE1BPDE1APDE1C | |
| SCHEMBL24067435 | 0.67 | PDE5A (0.41) | PDE5APDE10A | |
| SCHEMBL24604812 | 0.67 | MAPT (0.39) | — | |
| SCHEMBL21325055 | 0.66 | RIPK1 (0.33) | PDE1BSSTR4 | |
| SCHEMBL12775275 | 0.66 | EGFR (0.51) | PDE10AADRA1DADRA1AADRA1B | |
| SCHEMBL15315856 | 0.65 | KDM4E (0.52) | — | |
| SCHEMBL13019497 | 0.65 | ALDH1A1 (0.36) | PDE5A | |
| SCHEMBL24067418 | 0.65 | NOTUM (0.35) | PDE1BPDE1APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | PDE5A 494/4885PDE1B 740/4885PDE1A 608/4885 |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ENPP1, STING1, ENPP3 | PDE5A 150/4885PDE1B 143/4885PDE1A 92/4885 |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | PDE5A 494/4885PDE1B 740/4885PDE1A 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.